Delivery Order 75F40122D00006-75F40124F19004
Award Date
9/3/24
Potential Completion Date
1/19/27
Potential Value
$803K
Federal Agency
Food and Drug Administration
Awardee
Labstat International Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
B537 - Special Studies/Analysis- Medical/Health
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to Labstat International Inc., a for-profit limited liability company based in Canada. The $619,328.55 contract is for the chemical and physical characterization of pod and disposable e-cigarette aerosol. This order is part of a larger $45 million single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract held by Labstat...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded a $1,122,157.92 firm fixed price delivery order contract to Labstat International Inc., a foreign-owned for-profit organization, to conduct chemical, physical, and microbiological analyses of tobacco, e-cigarette, cannabis, and CBD products. This contract is part of a larger $45 million single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract with Labstat to provide tobacco laboratory services...
This federal contract award to Labstat International Inc., a leading analytical testing laboratory, is for a stability study of cigarette tobacco filler on behalf of the Food and Drug Administration (FDA). The firm fixed price delivery order is valued at $112,994.60 and has a completion date of June 13, 2016. Labstat has been awarded multiple prior contracts from the FDA to conduct chemical, physical, and microbiological analyses of tobacco, e-cigarette, cannabis, and CBD products in support...
The Food and Drug Administration awarded a definitive contract valued at $1,010,475.20 to Labstat International Inc., a foreign-owned for-profit organization, to evaluate the microbial parameters of electronic nicotine delivery system e-liquids. The contract calls for the contractor to validate test methods, conduct antimicrobial effectiveness testing, and measure water activity, total aerobic counts, endotoxins, glucans, and nitrosamines in laboratory-prepared and commercial e-liquid samples...
The U.S. Food and Drug Administration (FDA) awarded a $437,684.94 firm fixed price delivery order to Labstat International Inc., a leading analytical testing laboratory, to provide tobacco lab analysis services. The scope includes generating and quantitating benzo[a]pyrene, tar, nicotine, and carbon monoxide from pipe tobacco mainstream smoke under a new smoking regimen. This delivery order is part of a larger $45 million single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract...
This is a $1,215,324.40 Firm Fixed Price Delivery Order issued by the Food and Drug Administration (FDA) to Labstat International Inc., a leading analytical testing laboratory in Kitchener, Ontario. The contract is for Tobacco Lab Analysis Services and is part of a larger $45 million Indefinite Delivery Indefinite Quantity (IDIQ) contract awarded to Labstat to provide laboratory services in support of the FDA's regulatory oversight of tobacco products. The contract covers a range of technical...
This is a $467,253.90 firm fixed price delivery order contract awarded by the Department of Health and Human Services' Food and Drug Administration (FDA) to Labstat International Inc., a foreign-owned, for-profit organization. The contract is for the "Analysis of Matrix Specific HPHCS", which refers to the analysis of toxic constituents in tobacco, e-cigarette, cannabis, and CBD products to support the FDA's regulatory oversight. Labstat has been awarded multiple prior contracts by the...
The Department of Health and Human Services Food and Drug Administration awarded a $36,286,201 firm-fixed-price definitive contract to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to conduct a study on the toxicity of e-cigarette aerosol in in vivo nonclinical models. The contract does not have a set-aside designation and is scheduled for completion by February 28, 2025. Vamco, LLC, a small disadvantaged business, was awarded a subcontract to...
The U.S. Food and Drug Administration (FDA) awarded a $1,366,003.00 firm fixed-price delivery order contract to Research Triangle Institute (RTI International), a non-profit research organization, to determine the correlation between endotoxin and D-glucan concentration and microbial counts in open e-liquids. The contract has a period of performance through February 16, 2026 and was competitively awarded without any set-asides. RTI International is an experienced federal contractor, holding a...
This is a Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian agency, to The Fox Foundation Inc., a non-profit organization, for $3,408,203.00. The contract is to conduct a randomized, double-blinded, within-subjects, crossover clinical laboratory study to determine whether abuse liability, as measured by nicotine exposure, subjective measures, and product use behavior, differs between e-liquids formulated with tobacco-derived nicotine (TDN) and non-tobacco...